Gene therapy for collateral vessel development

Cardiovascular Research

Volumn 35, Issue 3, 1997, Pages 480-489

  Melillo, Guido ^a   Scoccianti, Marco ^a   Kovesdi, Imre ^b   Safi Jr , Jorge ^c   Riccioni, Teresa ^a,c   Capogrossi, Maurizio C ^a,c  

^a Laboratorio di Patologia Vascolare   (Italy)

^b GENVEC INC   (United States)

^c Laboratory of Cardiovascular Science   (United States)

Author keywords

Adenovirus; Angiogenesis; FGF; Gene therapy; Heparin; Ischemia; VEGF

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY DNA; GROWTH FACTOR; HEPARIN; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; CATTLE; COLLATERAL CIRCULATION; GENE TRANSFER; HEART INFARCTION; LIMB ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

COLLATERAL CIRCULATION; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTORS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; ISCHEMIA; LYMPHOKINES; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030780457     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00167-3     Document Type: Review

References (137)

1. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 267:1992;10931-10934.
2. Diaz-Flores L., Gutierrez R., Varela H. Angiogenesis: an update. Histol Histopathol. 9:1994;807-843.
3. Fan T.P., Jaggar R., Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci. 16:1995;57-66.
4. D'Amore P.A. Capillary growth: a two cell system. Semin Cancer Biol. 3:1992;49-56.
5. Shepro D., Morel N.M. Pericyte physiology. FASEB J. 7:1993;1031-1038.
6. Feigl E.O. Coronary physiology. Physiol Rev. 63:1983;1-205.
7. Olsson RA, Bugni WJ. Coronary circulation. In: Fozzard HA, Haber E, Jenning RB, Katz AM, Morgan HE, editors. The Heart and Cardiovascular System. New York: Raven Press, 1986:987-1037.
8. Mulvany M.J., Aalkjaer C. Structure and function of small arteries. Physiol Rev. 70:1990;921-961.
9. Myrhage R., Hudlicka O. Capillary growth in chronically stimulated adult skeletal muscle as studied by intravital microscopy and histological methods in rabbits and rats. Microvasc Res. 16:1978;73-90.
10. Capogrossi MC, Passaniti A. Angiogenesis in the lung. In: The Lung: Scientific Foundations. Philadelphia: Raven, 1997:2629-45.
11. Shaper W., Ito W. Molecular mechanisms of collateral vessel growth. Circ Res. 79:1996;911-919.
12. Mallett S., Barclay A.N. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today. 12:1991;220-223.
13. Basilico C., Moscatelli D. The FGF family of growth factors oncogenes. Adv Cancer Res. 59:1992;115-165.
14. Partanen J., Vainikka S., Korhonen J., Armstrong E., Alitalo K. Diverse receptors for fibroblast growth factors. Prog Growth Factor Res. 4:1992;69-83.
15. Fernig D.G., Gallagher J.T. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor. 3:1994;353-377.
16. Dionne C.A., Crumley G., Bellot F.et al. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J. 9:1990;2685-2692.
17. Holtrich U., Brauninger A., Strebhardt K., Rubsamen-Waigmann H. Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase. Proc Natl Acad Sci USA. 88:1991;10411-10415.
18. Millauer B., Wizigmann-Voos S., Schnurch H.et al. High affinity VEGF binding and development expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846.
19. De Vries C., Escobedo J.A., Ueno H.et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
20. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
21. Schutze S., Machleidt T., Kronke M. Mechanisms of tumor necrosis factor action. Semin Oncol. 19:1992;16-24.
22. Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J. Mechanism of activation of the TGF-beta receptor. Nature. 370:1994;341-347.
23. Stiles A.D., D'Ercole A.J. The insulin-like growth factors and the lung. Am J Respir Cell Mol Biol. 3:1990;93-100.
24. Resnicoff M., Coppola D., Sell C.et al. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor. Cancer Res. 54:1994;4848-4850.
25. Puri M.C., Rossant J., Alitalo K., Bernstein A., Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:1995;5884-5891.
26. Partanen J., Puri M.C., Schwartz L.et al. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development. 122:1996;3013-3021.
27. Sato T.N., Qin Y., Kozak C.A., Audus K.L. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA. 90:1993;9355-9358.
28. Davis S., Aldrich T.H., Jones P.F.et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 87:1996;1161-1169.
29. Suri C., Jones P.F., Patan S.et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1996;1171-1180.
30. Vikkula M., Boon L.M., Carraway K.L. 3rdet al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 87:1996;1181-1190.
31. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
32. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
33. Semenza G.L. Transcriptional regulation by hypoxia-inducible factor 1-molecular mechanisms of oxygen homeostasis. Trends Cardiovasc Med. 6:1996;151-157.
34. Stein I., Neeman M., Shweiki D., Itin A., Keshet E. Stabilization of vascular endothelial growth-factor messenger RNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol. 15:1995;5363-5368.
35. Hashimoto E., Ogita T., Nakaoka T.et al. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol. 267:1994;H1948-1954.
36. Tuder R.M., Flook B.E., Voelkel N.F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 95:1995;1798-1807.
37. Li J., Brown L.F., Hibberd M.G.et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 270:1996;H1803-H1811.
38. Sellke F.W., Wang S.Y., Stamler A.et al. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol. 271:1996;H713-H720.
39. Li J., Hampton T., Morgam J., Simons M. Stretch-induced TGF-beta release increases VEGF expression in the heart. Circulation. 94:1996;1-285.
40. Resnick N., Gimbrone M.A. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J. 9:1995;874-882.
41. More J.W.I., Sholley M.M. Comparison of the neovascular effects of stimulated macrophages and neutrophils in autologous rabbit corneas. Am J Pathol. 120:1985;87-98.
42. Sunderkotter C., Goebeler M., Schulze-Osthoff K., Bhardwaj R., Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther. 51:1991;195-216.
43. Burgess W.H., Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 58:1989;575-606.
44. Rubin J.S., Bottaro D.P., Chedid M.et al. Keratinocyte growth factor. Cell Biol Int. 19:1995;399-411.
45. Lorenzi M.V., Long J.E., Miki T., Aaronson S.A. Expression cloning, developmental expression, and chromosomal localization of fibroblast growth factor-8. Oncogene. 10:1995;2051-2055.
46. Miyamoto M., Naruo K., Seko C.et al. Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property. Mol Cell Biol. 13:1993;4251-4259.
47. Klagsbrun M. The fibroblast growth factor family: Structural and biological properties. Prog Growth Factor Res. 1:1989;207-235.
48. Givol D., Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J. 6:1992;3362-3369.
49. Friesel R.E., Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 9:1995;919-925.
50. Schlessinger J., Lax I., Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell. 83:1995;357-360.
51. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cell within collagen gels. Lab Invest. 69:1993;508-517.
52. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 189:1992;824-831.
53. Ferrara N., Winer J., Burton T. Aortic smooth muscle cells express and secret vascular endothelial growth factor. Growth Factors. 5:1991;141-148.
54. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 13:1992;18-32.
55. Connolly D.T. Vascular permeability factor: A unique regulator of blood vessel function. J Cell Biochem. 47:1991;219-223.
56. Houck K.A., Ferrara N., Winer J.et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 5:1991;1806-1814.
57. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial differentiation. Development. 114:1992;521-532.
58. Ladoux A., Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun. 195:1993;1005-1010.
59. Brogi E., Schatteman G., Wu T.et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest. 97:1996;469-476.
60. Shibuya M., Yamaguchi S., Yamane A.et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 5:1990;519-524.
61. Terman B.I., Carrion M.E., Kovacs E.et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene. 6:1991;1677-1683.
62. Shalaby F., Rossant J., Yamaguchi T.P.et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
63. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
64. Lee J., Gray A., Yuan J.et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA. 93:1996;1988-1992.
65. Joukov V., Pajusola K., Kaipanen A.et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:1996;290-298.
66. Kaplitt MD, Loewy AD, editors. Viral vectors. London: Academic Press, 1995.
67. Ledley F.D. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther. 6:1995;1129-1144.
68. Hodgson CP, editor. Retro-vectors for human gene therapy. Heidelberg: Springer, 1996.
69. Riessen R., Rahimizadeh H., Blessing E.et al. Arterial gene transfer using pure DNA applied directly to a hydrogel coated angioplasty balloon. Hum Gene Ther. 4:1993;749-758.
70. Isner J.M., Walsh K., Symes J.et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation. 91:1995;2687-2692.
71. Isner J.M., Pieczek A., Scainfeld R.et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
72. Isner JM, Pieczek A, Schainfeld R, et al. Arterial gene transfer of naked DNA in patients with critical limb ischemia. Circulation 1996;94:I-591 (Abstract).
73. Remy J.S., Sirlin C., Vierling P., Behr J.P. Gene transfer with a series of lipophilic DNA binding molecules. Bioconjug Chem. 5:1994;647-654.
74. Felgner P.L., Gadek T.R., Holm M.et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 84:1987;7413.
75. Middleton P.G., Caplen N.J., Gao X.et al. Nasal application of the cationic liposome DC-Chol: DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J. 7:1994;442-445.
76. Plautz G.E., Yang Z.Y., Wu B.Y.et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA. 90:1993;4645-4649.
77. San H., Yang Z.Y., Pompili V.J.et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther. 4:1993;781-788.
78. Puyal C., Milhaud P., Bienvenue A., Philippot J.R. A new cationic liposome encapsulating genetic material: A potential delivery system for polynucleotides. Eur J Biochem. 228:1995;697-703.
79. Legendre J.Y., Szoka F.C. Jr. Cyclic amphipathic peptide DNA complexes mediate high efficiency transfection of adherent mammalian cells. Proc Natl Acad Sci USA. 90:1993;893-897.
80. Demeneix B.A., Abdel Taweb H., Benoist C., Seignet I., Behr J.P. Temporal and spatial expression of lipospermine compacted genes transferred into chick embryos in vivo. Biotechniques. 16:1994;496-501.
81. Merwin J.R., Noell G.S., Thomas W.L.et al. Targeted delivery of DNA using YEE (GalNAcAH)3, a synthetic glycopeptide ligand for the glycoprotein receptor. Bioconjug Chem. 5:1994;612-620.
82. Crystal R.G. Transfer of genes to humans: Early lessons and obstacles to success. Science. 270:1995;404-410.
83. Shenk T. Group C adenoviruses as vectors for gene therapy. In: Kaplitt MD, Loewy AD, editors. Viral vectors. London: Academic Press, 1995:43-54.
84. Armentano D., Sookdeo C.C., Hehir K.M.et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther. 6:1995;1343-1353.
85. Krougliak V., Grahem F.L. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther. 6:1995;1575-1586.
86. Yeh P., Dedieu J.F., Orsini C.et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol. 70:1996;559-565.
87. Wang Q., Jia X.C., Finer M.H. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 2:1995;775-783.
88. Brough D.E., Lizonova A., Hsu C., Kulesa V.A., Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 70:1996;6497-6501.
89. Engelhardt J.F., Litzky L., Wilson J.M. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther. 5:1994;1217-1229.
90. Lee M.G., Abina M.A., Hadada H., Perricaudet M. The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 2:1995;256-262.
91. York I.A., Roop C., Andrews D.W.et al. A cytosolic herpes simplex virus protein inhibits antigen. Cell. 77:1994;525-535.
92. Harris J.D., Lemoine N.R. Strategies for targeted gene therapy. Trends Genet. 12:1996;400-405.
93. Krasnykh V.N., Mikheeva G.V., Douglas J.T., Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 70:1996;6839-6846.
94. Douglas J.T., Rogers B.E., Rosenfeld M.E.et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nature BioTech. 14:1996;1574-1578.
95. Wickham T.J., Roelvink P.W., Brough D.E., Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature BioTech. 14:1996;1570-1573.
96. Wickham T.J., Segal D.M., Roelvink P.W.et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 70:1996;6831-6838.
97. Wickham T.J., Roelvink P.W., Brough D.E., Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature BioTech. 14:1996;1570-1573.
98. Roelvink P.W., Kovesdi I., Wickham T.J. Comparative analysis of adenovirus fiber-cell interaction: Adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J Virol. 70:1996;7614-7621.
99. Safi J Jr, Gloe TR, DiPaula AF Jr, Becker LC, Capogrossi MC. Adenovirus-mediated gene transfer of acidic fibroblast growth factor reduces the risk region in a rabbit model of myocardial infarction. Circulation 1996;94:I-591 (Abstract).
100. Tsurumi Y., Takeshita S., Chen D. earnet al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 94:1996;3281-3290.
101. Giordano F.L., Ping P., McKirnan D.et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med. 2:1996;534-539.
102. Willard J.E., Landau C., Glamann D.B.et al. Genetic modification of the vessel wall. Comparison of surgical and catheter based techniques for delivery of recombinant adenovirus. Circulation. 89:1994;2190-2197.
103. Takeshita S., Weir L., Chen D.et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun. 227:1996;628-635.
104. Höckel M., Schlenger K., Doctrow S., Kissel T., Vaupel P. Therapeutic angiogenesis. Arch Surg. 128:1993;423-429.
105. Fujita M., Sasayama S., Asanoi H.et al. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation. 77:1988;1022-1029.
106. Hirai T., Fujita M., Nakajima H.et al. Importance of collateral circulation for prevention of left ventricular aneurysm formation in acute myocardial infarction. Circulation. 79:1989;791-796.
107. Yanagisawa-Miwa A., Uchida Y., Nakamura F.et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 257:1992;1401-1403.
108. Quyyumi A.A., Diodati J.G., Lakatos E., Bonow R.O., Epstein S.E. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study. J Am Coll Cardiol. 22:1993;635-641.
109. Chleboun J.O., Martins R.N., Mitchell C.A., Chrilla T.V. Basic FGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem Biophys Res Commun. 185:1992;510-516.
110. Pu L.Q., Sniderman A.D., Brassard R.et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 88:1993;208-215.
111. Khouri R.K., Hong S.P., Deune E.G.et al. De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor. J Clin Invest. 94:1994;1757-1763.
112. Cordeiro P.G., Seckel B.R., Lipton S.A.et al. Acidic FGF enhances peripheral nerve regeneration in vivo. Plast Reconstr Surg. 83:1989;1013-1019.
113. Eppley B.L., Doucet M., Connolly D.T., Feder J. Enhancement of angiogenesis by bFGF in mandibular bone graft healing in the rabbit. J Oral Maxillofac Surg. 96:1988;391-398.
114. Olech V.M., Kesahvjee S.H., Chamberlain D.W., Slutsky A.S., Patterson G.A. Role of bFGF in revascularization of rabbit tracheal autografts. Ann Thorac Surg. 52:1991;258-264.
115. Unger E.F., Sheffield C.D., Epstein S.E. Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model. Am J Physiol. 260:1991;H1625-H1634.
116. Yang H.T., Ogilvie R.W., Terjung R.L. Heparin increases exercise-induced collateral blood flow in rats with femoral artery ligation. Circ Res. 76:1995;448-456.
117. Mannarino E., Pasqualini L., Innocente S.et al. Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology. 42:1991;1-7.
118. Unger E.F., Banai S., Shou M.et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol. 266:1994;H1588-H1595.
119. Lazarous D.F., Scheinowitz M., Shou M.et al. Effects of chronic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation. 91:1995;145-153.
120. Shou M., Thirumurti V., Rajanayagam S.et al. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J Am Coll Cardiol. 29:1997;1102-1106.
121. Mannion JD, Magno MG, Spinale FG, et al. Basic fibroblast growth factor is associated with increased capillary density and preservation of muscle morphology in chronically stimulated, ischemic muscle. Circulation 1996:94,8:I-342 (Abstract).
122. Banai S., Jaklitsch M.T., Casscells W.et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res. 69:1991;76-85.
123. Pu L.Q., Snidermann A.D., Brassard R.et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 88:1993;208-215.
124. Takeshita S., Zheng L.P., Brogi E.et al. Therapeutic angiogenesis: A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 63:1994;662-670.
125. Bauters C., Asahara T., Zheng L.P.et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 21:1995;314-324.
126. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994;90:II228-34.
127. Banai S., Jaklitsch M.T., Shou M.et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 89:1994;2183-2189.
128. Lazarous D.F., Shou M., Scheinowitz M.et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 94:1996;1074-1082.
129. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92:II365-71.
130. Sellke F.W., Wang S.Y., Friedman M.et al. Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation. Am J Physiol. 267:1994;H1303-H1311.
131. Harada K., Friedman M., Lopez J.J.et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 270:1996;H1791-H1802.
132. Takeshita S., Tsurumi Y., Couffinahl T.et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest. 75:1996;487-501.
133. Mesri E.A., Federoff H.J., Brownlee M. Expression of vascular endothelial growth factor from a defective Herpes simplex virus type 1 amplicom vector induces angiogenesis in mice. Circ Res. 76:1995;161-167.
134. Mühlhauser J., Merrill M.J., Pili R.et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 77:1995;1077-1086.
135. Mühlhauser J., Pili R., Merrill M.J.et al. In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or non-secreted forms of acidic fibroblast growth factor. Hum Gene Ther. 6:1995;1457-1465.
136. Feldman L.J., Steg P.G., Zheng L.P.et al. Low-efficiency of percutaneous adenovirus-mediated gene transfer in the atherosclerotic rabbit. J Clin Invest. 95:1995;2662-2671.
137. Ware J.A., Simmons M. Angiogenesis in ischemic heart disease. Nature Med. 3:1997;158-164.